© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
July 22, 2013
Ibrutinib was well tolerated and highly effective in eradicating tumor cells in both treatment-naÃ¯ve and relapsed/refractory patients with chronic lymphocytic leukemia.
July 19, 2013
Using an intermittent dosing strategy with vemurafenib instead of continuous dosing has the potential to overcome the development of resistance in patients with melanoma treated with the drug.
July 18, 2013
A preliminary in vitro study has found markers that may predict response to drugs that target KRAS-mutated non-small cell lung cancer.
July 17, 2013
Two DNA demethylation biomarkers could potentially be used to more accurately determine response to epigenetic drugs for myelodysplastic syndromes.
July 16, 2013
Women with breast cancer who were carriers of the BRCA1 mutation had increased mortality compared with noncarriers in preliminary results from a retrospective study.
July 11, 2013
High levels of HER2 expression in metastatic breast cancer tumors correlated with increased benefit from treatment with adotrastuzumab.
July 09, 2013
The next-generation PI3 kinase (PI3K) inhibitor GDC-0032 has shown signs of efficacy in patients with advanced cancers that were mutated for the PI3K alpha gene.
July 08, 2013
Frontline cetuximab plus FOLFIRI improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wildtype metastatic colorectal cancer.
July 02, 2013
The anti-PD-1 therapy nivolumab demonstrated an overall objective response rate of 31%, with a median duration of 2 years in patients with advanced melanoma.
July 01, 2013
Combination therapy with ipilimumab and nivolumab led to durable tumor shrinkage in approximately half of patients with aggressive, advanced melanoma.
June 27, 2013
The second-generation TKI dacomitinib, designed to treat NSCLC, is being evaluated in a clinical trial that will measure the drugâ€™s effectiveness as a first-line treatment.
June 26, 2013
Head and neck squamous cell carcinomas have different patterns of genetic alterations, some of which may be druggable, according to a study by The Cancer Genome Atlas.
June 25, 2013
The recent approval of the second-generation proteasome inhibitor carfilzomib by the FDA comes nine years after the initial approval of bortezomib, the first-in-class drug of its type.
June 24, 2013
Interim findings from a phase III study indicate that sorafenib nearly doubled PFS for patients with differentiated thyroid cancer resistant to standard radioactive iodine therapy.
June 20, 2013
Although the use of CTCs as a â€œliquid biopsyâ€ to detect tumor growth has long been a goal, developing the technology for detecting and analyzing CTCs has been a challenge.
June 19, 2013
A phase I study found that idelalisib produced rapid and prolonged tumor shrinkage in half of patients with relapsed or refractory CLL who received the drug as monotherapy.
June 18, 2013
MPDL3280A, an antibody that targets the programmed death ligand 1 (PD-L1), demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors.
June 17, 2013
The progression of prostate cancer to castration-resistant prostate cancer is a crucial change in the behavior of this cancer. Bony metastasis is a common finding that may cause symptoms such as pain.